Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.
“This [presentation is] basically highlighting the activity of this GPRC5D CAR T-cell product in earlier rounds of therapy in a high-risk patient population, the favorable toxicity profile, and a very high response rate of 96% with a complete response rate of 32%.”
BMS-986393, a GPRC5D-targeted chimeric antigen receptor (CAR) T-cell therapy, was well-tolerated and yielded responses in patients with multiple myeloma and 1-to-3 lines of prior therapy.
Initial data from the phase 1 CC95266MM001 study (NCT04674813) evaluating BMS-986393 were presented at the European Hematology Association 2024 Hybrid Congress, held June 13-16 in Madrid, Spain, and virtually, by Omar Nadeem, MD, medical oncologist and clinical director, Myeloma Cellular Therapies Program, Dana-Farber Cancer Institute and instructor in medicine, Harvard Medical School.
The data are from 31 participants in the study who received 150 x 106 CAR T cells. Only 1 patient had received prior anti-BCMA therapy. Investigators found that overall response rate of 96%, with a complete responses rate of 32%, although median follow-up time was only 3.2 months (range, 0.5–5.8) at the time of data cutoff. CGTLive® spoke with Nadeem to learn more about the new data. He shared that the therapy's toxicity profile was as expected and gave an overview of treatment-emergent adverse events that occurred, including some neurological toxicities. He noted that follow-up time was short in this data and that responses may deepen as follow-up lengthens.
